Tratamiento de conversión en población no seleccionada
PRIME study post-hoc analysis. Resection rates (WT
RAS
and LLD)
•
Douillard JY, et al. Eur J Cancer 2015;51:1231−42.
•
*Descriptive P-value (Fisher exact test).
Patients (%)
∆ = 6.5%
P = 0.644*
Any resection
0
10
20
30
Panitumumab + FOLFOX4 (n = 48)
35
25
15
5
Complete resection
FOLFOX4 (n = 41)
Updated analysis
33%
27%
31%
17%
∆ = 14.2%
P = 0.145*
